Prodrugs of 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide
申请人:Boehringer Ingelheim Pharma GmbH & Co. KG
公开号:US20040059118A1
公开(公告)日:2004-03-25
The present invention relates to new compounds of general formula
1
having thrombin-inhibiting activity. Exemplary are:
1-Methyl-2-[4-(N-hydroxyamidino)-phenylaminomethyl]-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-ethoxycarbonylethyl)-amide, and
1-Methyl-2-[4-(N-methoxycarbonylamidino)-phenylaminomethyl]-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide.
本发明涉及通式为
1
具有凝血酶抑制活性。例如
1-甲基-2-[4-(N-羟基氨基)-苯氨基甲基]-苯并咪唑-5-基-羧酸-(N-2-吡啶基-N-2-乙氧基羰基乙基)-酰胺,以及
1-Methyl-2-[4-(N-methoxycarbonylamidino)-phenylaminomethyl]-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide.